NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/21/2025
Back to search
Official data from USPTO
G2B GATE2BRAIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
11/23/2025
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
12/30/2020
Registration date
06/07/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/07/2022
Last transaction
11/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
ES
Examiner
MCCARTHY,BRIDGET ANN
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "G2B", where the "G2" is in blue font and the letter "B" is in orange font, and the "2B" is underlined in blue, all surrounded by a blue circle. To the right of "G2B" is the stylized wording "GATE2BRAIN", where the wording "GATE2" is in blue font and the term "BRAIN" is in orange font.
Holders and representatives
Holders
Gate2Brain S.L.
Representatives
Justin R. Young DTL Ltd.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical compositions and materials for scientific usechemicals for use in biomedicine and pharmaceutical sciences; proteins for use in science and industry; proteins for pharmaceutical industry; chemical substancesbiochemical substances and natural elementspeptides and proteins for use in the manufacture of pharmaceutical and veterinary products; chemical preparations for scientific use other than for medical or veterinary use
Class 5
Pharmaceutical products for the treatment of brain related diseases and conditions; medicinal and veterinary products and preparationspreparations for the treatment of central nervous system diseases and conditions; regulatory proteins for medical use for the treatment of central nervous system diseases and conditions; synthetic peptides for pharmaceutical use for the treatment of brain diseases and conditions; vaccines; drug delivery agents in the form of suspensioninjectable solutionmicellesmicellar solutionsolid powderliophilized powder that facilitate the administering of medicines across biological barriers; pharmaceutical agents acting on metabolism; therapeutic products of bacterial originsmall moleculesproteins and peptides for the treatment of brain diseases; biological preparations for medical use for the treatment of brain diseases and conditions; probiotic bacterial formulations for medical use for the treatment of brain diseases and conditions; stem cells for medical use; nutraceuticals for therapeutic use for the treatment of brain diseases and conditions; pharmaceutical preparations for activating cellular function; chemico-pharmaceutical preparations for the treatment of brain diseases and conditions; dietetic preparations and supplements adapted for medical purposes; nutritional supplements; nutritional supplements for veterinary use; dietary supplements for veterinary use
Class 42
Scientific servicesscientific research and testing in the field of drug delivery across biological barriers; research servicespharmaceutical and biomedical research services; research regarding pharmaceutical productspharmaceutical research services; scientific research in the field of chemistry; biotechnological research; biochemical research and analysis; research and development services in the field of bacteriology; research and development services in the field of vaccines; medical and pharmacological research; scientific research in the fields of biochemistry and biotechnology; food research; stem cell research; development of pharmaceutical products; conducting clinical trials for others relating to pharmaceutical products; development of pharmaceutical preparations and medicines; bacteriological research and consultancy; scientific consultancy relating to research and development in the field of therapeutics; providing information and data services about medical and veterinary research and development; scientific consultancy services; provision of medical research information regarding results of clinical trials relating to pharmaceutical products
Publications
History of USPTO decisions and trademark events.
37 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/07/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/23/2022
FIMP
FINAL DISPOSITION PROCESSED
09/22/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/07/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/07/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/07/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/22/2022
PUBO
PUBLISHED FOR OPPOSITION
03/22/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/02/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/02/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/02/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/14/2022
ALIE
ASSIGNED TO LIE
02/14/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
02/11/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/11/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
02/11/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/14/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/14/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/14/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/17/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/17/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/17/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/17/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/17/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/17/2021
RFNT
REFUSAL PROCESSED BY IB
08/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/14/2021
RFRR
REFUSAL PROCESSED BY MPU
07/14/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/09/2021
CNRT
NON-FINAL ACTION WRITTEN
07/08/2021
DOCK
ASSIGNED TO EXAMINER
07/04/2021
MAFR
APPLICATION FILING RECEIPT MAILED
02/27/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/23/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/18/2021
Continuous trademark protection
Get notified about every new filing that threatens G2B GATE2BRAIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.